Generic Name and Formulations:
Bupivacaine 13.3mg/mL; liposome injectable suspension; preservative-free.
Pacira Pharmaceuticals, Inc.
For administration into the surgical site to produce postsurgical analgesia.
For single-dose administration only. Base dose on surgical site and volume required to cover area. Inject slowly into soft tissue via infiltration. Bunionectomy: 106mg (volume: 8mL). Hemorrhoidectomy: 266mg (volume: 20mL). See literature for administration.
<18yrs: not recommended.
Local anesthetic (amide-type).
Obstetrical paracervical block.
Not interchangeable with other forms of bupivacaine. Avoid intravascular inj. To be administered under the supervision of experienced clinicians. Cardiovascular disease. Hepatic or renal impairment. Monitor cardiovascular and respiratory vital signs. Pregnancy (Cat.C), nursing mothers: not recommended.
Do not dilute with water or hypotonic agents (may result in disruption of liposomal particles). Do not mix with lidocaine or other non-bupivacaine-based local anesthetics. Do not administer other forms of bupivacaine within 96hrs following administration of Exparel. May administer after at least 20 minutes following local administration of lidocaine.
Nausea, constipation, vomiting, pyrexia, dizziness, edema peripheral, anemia, hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain; CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tremors), cardiovascular effects (eg, myocardium depression, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, spinal block, urinary retention, paresthesia, weakness, headache, paralysis of lower extremities).
Single-use vial (20mL)—10